The announcement of positive initial results from a key clinical trial (IMVT-1402 Phase 1 SAD and 300 mg subcutaneous MAD) has led to an increase in Roivant Sciences' stock price. This is because positive trial results often indicate potential future revenue from the product under trial, which can lead to increased investor confidence and demand for the stock.